Why the study?
Do substituted pyrazolyl piperidine derivatives inhibit human platelet aggregation compared to aspirin in vitro?
Do substituted pyrazolyl piperidine derivatives inhibit human platelet aggregation compared to aspirin in vitro?
Novel pyrazolyl piperidine derivatives demonstrate potent in vitro antiplatelet activity superior to aspirin, highlighting their potential for future drug development.
These derivatives may merit further preclinical testing; leaves open efficacy in human platelets or clinical translation.
The synthesis and antiplatelet activity of substituted pyrazolyl piperidine derivatives ( 3a–n ) are described. These compounds were synthesized by an improved ring opening reaction of 2‐arylidene quinuclidinone using hydrazine hydrate under mild conditions. They were characterized and screened for their in vitro antiplatelet profile in human platelet aggregation using adenosine diphosphate as agonist. Investigation of structure activity relation revealed interesting results. Among these synthesized derivatives ( 3a–n ), compounds 3a , 3c , 3j , and 3l exhibited excellent activity, while 3c was the most potent one. Based on IC 50 values, it was observed that most of the compounds possessed antiplatelet aggregation activity superior to the reference drug Aspirin.
No takes yet. Share an insight, caveat, or question.
Soni et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: